Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People Briefs: Covidien CFO To Retire; Appointments At ConvaTec, Metamark, NeuroSigma, Uroplasty

This article was originally published in The Gray Sheet

Executive Summary

Covidien Chief Financial Officer Charles Dockendorff announces retirement. ConvaTec, Metamark, NeuroSigma and Uroplasty appoint executives. More people briefs.

You may also be interested in...



Two Device Industry Veterans Join Boston Scientific’s Board

Hologic CEO Stephen MacMillan and former Covidien exec Charles Dockendorff have been elected to Boston Scientific’s board of directors, adding significant device industry expertise to the mix. MacMillan will be the only active device industry CEO for another company on the board.

People Briefs: CEO At LifeScience Alley; Orthofix, Exact Sciences Appoint Board Chairs

LifeScience Alley CEO Dale Wahlstrom retires and Shaye Mandle named successor. Orthofix International and Exact Sciences name new board chairs. Wound Management appoints new CFO, director of R&D and chief medical officer. Other people news.

News Briefs: Lung Screening Recs; Stryker Purchase; CMS News

Federal task force issued final recommendations advising CT screening for people at high risk for lung cancer. Stryker acquired Patient Safety Technologies. CMS announced updates on accountable care organizations. More news briefs.

Related Content

Topics

UsernamePublicRestriction

Register

MT033562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel